rucolan®
bayer ag - dithianon - granulé dispersible dans l'eau (wg) - 70 % ; - 70 % dithianon - fongicide ;
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibrose kystique - autres produits du système respiratoire - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 et 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 et 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
enzepi
allergan pharmaceuticals international ltd - poudre de pancréas - insuffisance pancréatique exocrine - digestives, incl. enzymes - traitement de remplacement de l'enzyme pancréatique dans l'insuffisance pancréatique exocrine due à la fibrose kystique ou à d'autres. pancréatite chronique, post-pancréatectomie ou cancer du pancréas). enzepi est indiqué chez les nourrissons, les enfants, les adolescents et les adultes.
eryc delayed-release capsules capsule (entérosoluble)
pfizer canada ulc - Érythromycine - capsule (entérosoluble) - 250mg - Érythromycine 250mg - erythromycins
eryc delayed-release capsules capsule (entérosoluble)
pfizer canada ulc - Érythromycine - capsule (entérosoluble) - 333mg - Érythromycine 333mg - erythromycins
moon® experience
bayer ag - fluopyram; tébuconazole - suspension concentrée (sc) - 17.6 %200 g/l; 17.6 %200 g/l; - 200 g/l fluopyram; 200 g/l tébuconazole - fongicide ;
moon® privilege
bayer ag - fluopyram - suspension concentrée (sc) - 41.7 %500 g/l; - 500 g/l fluopyram - fongicide ;
moon® sensation
bayer ag - trifloxystrobine; fluopyram - suspension concentrée (sc) - 21.4 %250 g/l; 21.4 %250 g/l; - 250 g/l fluopyram; 250 g/l trifloxystrobine - fongicide ;
prodigy®
bayer ag - méthoxyfénozide - suspension concentrée (sc) - 22.5 %240 g/l; - 240 g/l méthoxyfénozide - insecticide ;
sidroga brust- und hustentee arzneitee
sidroga ag - la racine de réglisse, althaeae de feuilles, de la banane plantain lanceolatae de feuilles, de thymidine herbe, anisi stellati fruits, althaeae racine, foeniculi fruits, lichen islandicus, salviae trilobae feuille, rhoeados fleur - arzneitee - la racine de réglisse, de 31,2 %, althaeae feuille de 11 %, le plantain lanceolatae feuille de 11 %, de thymidine herbe de 11 %, anisi stellati fruits de 7,3 %, althaeae la racine de 5,5 %, foeniculi fruits de 5,5 %, lichen islandicus de 5,5 %, salviae trilobae feuille de 5,5 %, rhoeados fleur de 6,5 %, pour le papier et 1,5 g. - bei übermässiger bildung von zähem schleim z. b. bei erkältungshusten - phytoarzneimittel